Click to view our statement on Accessibility
Back
In the News

Louis Lehot on Biotech IPOs – 'Biotech could have a great fourth quarter'

04 September 2024 Bloomberg Law

People

Louis Lehot

Partner

Silicon Valley 650.251.1222

Related News

View All Posts
26 September 2024 In the News

Gregory Marino on NIL Litigation – 'Schools want to know where the line is, and now everything is in flux'

Foley & Lardner LLP special counsel Gregory Marino shared insight on the growing complexities of collegiate sports in the ABA Journal article, "Money and litigation tangle with recent rules for college athletes' NIL deals."
24 September 2024 In the News

Thomas Ferrante Assesses Recent HHS OIG Report on Remote Patient Monitoring

Foley & Lardner LLP partner Thomas Ferrante commented on the recently released report on remote patient monitoring from the U.S. Department of Health and Human Services Office of Inspector General (OIG) in the Fierce Healthcare article, “HHS watchdog flags potential remote monitoring fraud. Stakeholders say concerns about misuse are overblown.”
20 September 2024 In the News

David Rosen Featured for Insight on Looming FDA Final Rule for Cosmetic Manufacturing

Foley & Lardner LLP partner David Rosen is featured by CosmeticsDesign for his insights on the U.S. Food and Drug Administration's final rule establishing Good Manufacturing Practices for the cosmetics industry in the article, "Preparing for MoCRA’s 2025 cGMP deadline: What cosmetic manufacturers and suppliers need to know."